Early signs are positive for CureVac and GSK's mRNA collaboration

31 January 2023

gene_genetic_test_biotech_biomarker_lab_research_2022_big

mRNA specialist CureVac (Nasdaq: CVAC) has reported positive data from key Phase I programs in COVID-19 and seasonal flu.

The German company is working with British pharma major GSK (LSE: GSK) on the vaccine programs, under the terms of a collaboration that was agreed in 2020.

GSK took a 10% stake in the company at that time, at a cost of $163 million, in addition to making a significant upfront payment and committing to substantial milestone payments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK